This trial is active, not recruiting.

Conditions congestive heart failure, heart disease
Treatments cardiac resynchronization pacemaker (insync sentry or concerto, medtronic, minneapolis, mn,usa) with two intracardiac leads, triple-site cardiac resynchronization
Phase phase 2/phase 3
Sponsor Silesian Centre for Heart Diseases
Start date February 2008
End date July 2010
Trial size 100 participants
Trial identifier NCT00814840, SilesianCHD-KNW-6501-3/08


The purpose of this study is to assess the efficiency of permanent biventricular pacing using three ventricular leads in terms of reduction in adverse cardiac events rates, improvement in cardiac capacity and patients' functional status in subjects with congestive heart failure and a physiologic (sinus) rhythm.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
(Active Comparator)
Triple-site resynchronization group
triple-site cardiac resynchronization
Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
(Active Comparator)
Standard (double-site) resynchronization group
cardiac resynchronization pacemaker (insync sentry or concerto, medtronic, minneapolis, mn,usa) with two intracardiac leads
Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)

Primary Outcomes

Combined end-point of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in VO2max and ≥10% in 6MWD.
time frame: six months

Secondary Outcomes

The occurrence of major adverse cardiovascular events (hospitalization for exacerbated HF requiring modification of pharmacotherapy, heart transplant or death).
time frame: five years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age 18 or more, - Congestive heart failure (HF) in NYHA class III-IV within last 90 days despite optimal medical treatment, - Left ventricular ejection fraction (EF) <=35% measured with echocardiography, - Sinus rhythm >90% of the time in 24-h Holter monitoring 1-3 days prior to randomization, - Inter- or intraventricular mechanical dyssynchrony ≥40ms measured with pulse Doppler and tissue Doppler echocardiography, - Optimal pharmacotherapy during the last 90 days, - Signed informed, written consent. Exclusion Criteria: - Pregnancy or breastfeeding, - Unstable HF requiring hospitalization with intravenous inotropic drugs within last 90 days, - Myocardial infarction, percutaneous/surgical revascularization or any cardiosurgical procedure within 90 days prior to randomization, - Stroke within last 90 days, - History of chronic or persistent atrial fibrillation, flutter, tachycardia, - Acute myocarditis, - Implanted previously pacemaker, ICD or CRT-device, - Participation in a concurrent trial that could confuse the results of this study, - Mechanical right heart valve, - Prior heart transplant, - Valvular disease that is indication for valve surgery, - Coronary heart disease if percutaneous or surgical revascularization is indicated and possible, - Any state, apart from HF, that limits the estimated survival time to <1 year, - Unwillingness or inability to understand the nature of the study, to participate or to give written informed consent.

Additional Information

Official title Triple-Site Versus Standard Cardiac Resynchronization Therapy (TRUST CRT) Randomized Trial
Principal investigator Radosław Lenarczyk, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in February 2014.
Information provided to ClinicalTrials.gov by Silesian Centre for Heart Diseases.